Clinical trial
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not…
NCT00005960 · Amgen, Industry · Unknown status
Key facts
| NCT number | NCT00005960 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | A Phase II Study of Doxorubicin and Cyclophosphamide With Sequential Docetaxel in Patients With Hormone-Refractory Prostate Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain, Prostate Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride, pain therapy |
| Start date | Oct 1, 1999 |
| First posted | Jun 8, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: